Companies / SOLV vs BSX
SOLV vs BSX: Solventum and Boston Scientific
Solventum (SOLV) reported $8.3B in revenue against a 18.7% net margin, while Boston Scientific (BSX) reported $20.1B at a 14.4% net margin, most recently.
| Metric | SOLV | BSX |
|---|---|---|
| Revenue | $8.3B | $20.1B |
| Net Income | $1.6B | $2.9B |
| Gross Margin | 53.5% | 69.0% |
| Operating Margin | 26.2% | 18.0% |
| EPS (Diluted) | $8.88 | $1.94 |
| Free Cash Flow | $-10.0M | $3.7B |
| Total Debt | $5.0B | $11.4B |
| P/E Ratio | 8.9× | 49.2× |
| P/B Ratio | 2.7× | n/m |
| Stock Price | $87.11 | $44.62 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| SOLV Revenue | $8.1B | $8.2B | $8.3B | $8.3B |
| BSX Revenue | $12.7B | $14.2B | $16.7B | $20.1B |